Dabur India Limited (DABUR)
🎯 Key Takeaways
- Dabur India is transitioning from a mature FMCG player to a growth-oriented consumer conglomerate, leveraging rural market resilience and digital channels to offset urban softness. The company demonstrated consistent profitability expansion and rural demand outperformance in FY26, supported by strategic investments in e-commerce and emerging categories like nutraceuticals.
- Revenue grew 10.8% QoQ to ₹3,355 in Q3FY25.
- ⚠️ USFDA observations on the Silvassa plant, while non-material, could attract regulatory scrutiny if repeated across facilities.
📖 The Story
Dabur India is transitioning from a mature FMCG player to a growth-oriented consumer conglomerate, leveraging rural market resilience and digital channels to offset urban softness. The company demonstrated consistent profitability expansion and rural demand outperformance in FY26, supported by strategic investments in e-commerce and emerging categories like nutraceuticals.
📰 What's Happening
In Q4 FY26, Dabur reported a 16% YoY rise in consolidated net profit to Rs 362 crore, driven by 7.3% revenue growth and strong rural demand (+350bps outperformance). Management highlighted double down on emerging channels including quick commerce and D2C nutraceutical brand SIENS. The company also incorporated a Delaware-based subsidiary, PRAVAAH CONSUMER GROUP INC., to accelerate global expansion. Additionally, Dabur confirmed USFDA audit concerns were limited to a non-material plant with no operational or financial impact.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,678 | 3,130 | 3,204 | 3,255 | 2,815 | 3,349 | 3,029 | 3,355 |
| Operating Profit | 531 | 715 | 777 | 795 | 596 | 784 | 704 | 810 |
| OPM % | 15.3% | 19.3% | 20.6% | 20.5% | 16.6% | 19.6% | 18.2% | 20.3% |
| Net Profit | 293 | 457 | 507 | 506 | 341 | 494 | 418 | 516 |
| EPS | ₹1.70 | ₹2.62 | ₹2.91 | ₹2.90 | ₹1.97 | ₹2.82 | ₹2.40 | ₹2.95 |
Operating margins have stabilized above 19% over the past four quarters, with Q4 FY26 OPM at 20.3%, reflecting pricing power and cost discipline. Net profit growth accelerated to 16% YoY in Q4, outpacing the 5% revenue growth, indicating improved profitability. Full-year FY26 net profit rose 7.4% to Rs 1,869 crore on modest 5% revenue growth, underscoring margin resilience. Sequential revenue trends show volatility, but rural and e-commerce channels are emerging as key growth engines.
🔮 Management Outlook & What's Next
Management expects rural-urban growth convergence to continue, with targeted investments in quick commerce and direct-to-consumer nutraceutical platforms. The company is positioning emerging channels as core growth levers, signaling a strategic shift beyond traditional retail. No formal long-term guidance was provided, but capital allocation appears aligned with digital and rural market expansion.
Extracted from official company announcements. Not StockFin.ai's opinion.
⚖️ Peer Comparison — Personal Products
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Godrej Consumer Products Limited | 1.06 L Cr | -234.6 | — | — | — |
| Dabur India Limited | 82,955 | 46.1 | — | — | — |
| Colgate Palmolive (India) Limited | 58,749 | 44.3 | — | — | — |
| Procter & Gamble Hygiene and Health Care Limited | 31,506 | 36.7 | — | — | — |
| Gillette India Limited | 25,438 | 41.0 | — | — | — |
| Emami Limited | 18,684 | 23.6 | — | — | — |
| Cupid Limited | 16,184 | 668.7 | — | — | — |
| Honasa Consumer Limited | 11,518 | 145.1 | — | — | — |
| Bajaj Consumer Care Limited | 7,020 | 58.5 | — | — | — |
| JHS Svendgaard Laboratories Limited | 80 | -5.8 | — | — | — |
⚠️ Risk Factors
1. USFDA observations on the Silvassa plant, while non-material, could attract regulatory scrutiny if repeated across facilities. 2. Rural demand, though currently resilient, remains vulnerable to agricultural income and monsoon variability. 3. Margin expansion is increasingly reliant on digital and emerging channels, which are still nascent and unproven at scale.
📋 Recent Filings
-
Announcement 11 June 2026Dabur India disclosed that the US FDA issued Import Alert 66-40 on June 10, 2026, concerning data integrity issues at its Silvassa plant, but emphasiz...
-
regulation 31 3 June 2026No summary available
-
Announcement 2 June 2026Dabur India announced its participation in two upcoming investor conferences in London and Mumbai on June 8-9, 2026, as part of scheduled analyst and ...
-
🔴 Announcement 1 June 2026Dabur India clarified that USFDA observations on its Silvassa plant affect only a small revenue-generating unit, which remains operational, and confir...
-
Announcement 25 May 2026Dabur India announced its schedule for upcoming investor conferences on June 1 and June 2, 2026, in Mumbai, where company officials will meet analysts...
-
🔴 Announcement 19 May 2026Dabur India announced the incorporation of a new step-down subsidiary, PRAVAAH CONSUMER GROUP INC., in Delaware, USA, effective May 1, 2026, as part o...
-
🔴 annual report 7 May 2026No summary available
-
🔴 Corporate Action 7 May 2026Dabur India announced a final dividend of ₹5.50 per share (550% on par) aggregating to ₹975.53 crores for FY 2025-26, following audited results showin...
-
🔴 Financial Results 7 May 2026Dabur India reported a 16% year-on-year increase in consolidated net profit to Rs 362 crore for Q4 2025-26, driven by 7.3% revenue growth to Rs 3,038 ...
-
🟡 Board Meeting 7 May 2026Dabur India announced its audited FY 2025-26 results on May 7, 2026, reporting a final dividend of **₹5.50 per share** (550% of face value) subject to...
🧠 Analyst's Read
Dabur is executing a quiet but meaningful transformation, using rural strength and digital channels to reignite growth. Investors should monitor the pace of adoption in quick commerce and nutraceuticals, as well as management's ability to convert strategic bets into sustainable margins.
Based on filing content and financial data. Not a recommendation.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-06-16.